Core Viewpoint - WuXi AppTec's subsidiary, WuXi Biologics, has seen a significant stock price increase following the announcement that its CAR-T product, Beinuoda, has been included in the first version of the National Healthcare Security Administration's commercial health insurance innovative drug list in China [1] Group 1: Company Developments - WuXi Biologics' stock rose over 9% in early trading, currently up 7.79% at HKD 3.32, with a trading volume of HKD 2.6756 million [1] - The company announced that Beinuoda (Ruxolitinib injection) is the first domestically developed CAR-T product approved as a Class 1 new drug in China [1] Group 2: Product Information - Beinuoda is currently the only CAR-T product in China approved for three non-Hodgkin lymphoma indications: relapsed/refractory large B-cell lymphoma, relapsed/refractory follicular lymphoma, and relapsed/refractory mantle cell lymphoma [1] - Prior to its inclusion in the national commercial insurance innovative drug directory, Beinuoda had already been included in over 100 affordable insurance plans and nearly 100 million medical insurance plans, demonstrating its significant clinical value and extensive real-world research validation among Chinese patients [1]
港股异动 | 药明巨诺-B(02126)早盘涨超9% 倍诺达®获纳入国家医保局商保创新药目录